Ivabradine in the treatment of heart failure Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2017
Keywords:
chronic heart failure, ivabradine, β-blockers, combination therapy

Main Article Content

Michał Ciurzyński
Klinika Chorób Wewnętrznych i Kardiologii z Centrum Diagnostyki i Leczenia Żylnej Choroby Zakrzepowo-Zatorowej, Warszawski Uniwersytet Medyczny, Szpital Kliniczny Dzieciątka Jezus

Abstract

In June 2016 „European Heart Journal” published the guidelines of the European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. This document updates the data on the diagnosis and management of patients with heart failure. This guidelines emphasize that ivabradine improves prognosis in patients with chronic heart failure. According to the guidelines ivabradine should be considered to reduce the risk of heart failure hospitalization or cardiovascular death in symptomatic patients with LVEF ≤ 35%, in sinus rhythm and a resting heart rate ≥ 70 bpm despite treatment with an evidence-based dose of β-blocker (or maximum tolerated dose below that), ACE-I (or ARB), and an MRA (or ARB). The article presents the most important data concerning the use of ivabradine in patients with heart failure and describes the case of a patient with severe heart failure, in which the ivabradine was used.

Article Details

How to Cite
Ciurzyński, M. (2017). Ivabradine in the treatment of heart failure. Medycyna Faktow (J EBM), 10(1(34), 22-25. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2164
Issue
Vol 10 No 1(34) (2017)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Ponikowski P., Voors A.A., Anker S.D. et al.; The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37(27): 2129-2200.
2. Mosterd A., Hoes A.W.: Clinical epidemiology of heart failure. Heart 2007; 93(9): 1137-1146.
3. Bleumink G.S., Knetsch A.M., Sturkenboom M.C. et al.: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart J. 2004; 25(18): 1614-1619.
4. Solomon S.D., Dobson J., Pocock S. et al.: Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116(13): 1482-1487.
5. Swedberg K., Komajda M., Bohm M. et al.: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-885.
6. Bohm M., Borer J., Ford I. et al.: Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol. 2013; 102(1): 11-22.